Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12511897 | 0.81 | MAPT (0.47) | ALDH1A1MAPTGAALMNAALOX15 | |
| SCHEMBL13019509 | 0.76 | ALDH1A1 (0.39) | ALDH1A1MAPTLMNAALOX15KMT2A | |
| SCHEMBL12715299 | 0.74 | ALDH1A1 (0.38) | ALDH1A1MAPTGAALMNAALOX15 | |
| SCHEMBL12216645 | 0.74 | ALDH1A1 (0.38) | ALDH1A1MAPTGAALMNAALOX15 | |
| SCHEMBL13966824 | 0.70 | ALDH1A1 (0.49) | ALDH1A1MAPTALOX15KMT2AMEN1 | |
| SCHEMBL13890918 | 0.68 | ALDH1A1 (0.34) | ALDH1A1MAPTGAALMNAALOX15 | |
| SCHEMBL16317102 | 0.67 | MAPT (0.47) | ALDH1A1MAPTGAAKMT2AMEN1 | |
| SCHEMBL6261982 | 0.64 | BCHE (0.53) | ALDH1A1MAPTALOX15KMT2AMEN1 | |
| SCHEMBL12511299 | 0.64 | ALDH1A1 (0.53) | ALDH1A1MAPTLMNAALOX15KMT2A | |
| SCHEMBL13716111 | 0.63 | NR1H4 (0.44) | ALDH1A1GAALMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039630-B2 | Cationic compound, dye compound and method of using the same, and optical information recording medium | FUJIFILM CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| US-8039630-B2 | Cationic compound, dye compound and method of using the same, and optical information recording medium | FUJIFILM CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20090130367-A1 | CATIONIC COMPOUND, DYE COMPOUND AND METHOD OF USING THE SAME, AND OPTICAL INFORMATION RECORDING MEDIUM | FUJIFILM CORPORATION (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090130367-A1 | CATIONIC COMPOUND, DYE COMPOUND AND METHOD OF USING THE SAME, AND OPTICAL INFORMATION RECORDING MEDIUM | FUJIFILM CORPORATION (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20080165668-A1 | RECORDING MEDIUM AND INFORMATION RECORDING AND REPRODUCING METHOD USING THE SAME | FUJIFILM CORPORATION | 2008-07-10 | — | — | US | disclosed |
| US-20080165668-A1 | RECORDING MEDIUM AND INFORMATION RECORDING AND REPRODUCING METHOD USING THE SAME | FUJIFILM CORPORATION | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090130367-A1 | CATIONIC COMPOUND, DYE COMPOUND AND METHOD OF USING THE SAME, AND OPTICAL INFORMATION RECORDING MEDIUM | CHRM1, CHRM2, TRPC6 | ALDH1A1 1010/4885MAPT 3569/4885GAA 4416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.